Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02602860
Recruitment Status : Completed
First Posted : November 11, 2015
Last Update Posted : October 30, 2017
Sponsor:
Collaborators:
PRA Health Sciences
Yale University
Information provided by (Responsible Party):
UCB Pharma

Brief Summary:
This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe [11C]UCB-J exits the brain when Levetiracetam or Brivaracetam are given. This will be used to estimate how fast the antiepileptic drugs enter the brain.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Radiation: [11C]UCB-J Drug: Brivaracetam Drug: Levetiracetam Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Single-center, Open-label Positron Emission Tomography Study to Evaluate the Time-course of Displacement of [11C]UCB-J by Brivaracetam and Levetiracetam in Healthy Volunteers
Actual Study Start Date : November 2015
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Levetiracetam

Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.

Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm.

Radiation: [11C]UCB-J
  • Pharmaceutical form: Sterile solution for intravenous infusion
  • Concentration: 20 mCi
  • Route of Administration: iv
Other Name: [11C]APP311

Drug: Levetiracetam
  • Pharmaceutical form: Sterile solution for intravenous infusion
  • Concentration: 100 mg/ml
  • Route of Administration: iv
Other Names:
  • Keppra
  • L059

Experimental: Brivaracetam

Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.

Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.

Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg.

Radiation: [11C]UCB-J
  • Pharmaceutical form: Sterile solution for intravenous infusion
  • Concentration: 20 mCi
  • Route of Administration: iv
Other Name: [11C]APP311

Drug: Brivaracetam
  • Pharmaceutical form: Sterile solution for intravenous infusion
  • Concentration: 10 mg/ml
  • Route of Administration: iv
Other Name: UCB34714

Drug: Brivaracetam
  • Pharmaceutical form: Tablets for oral intake
  • Concentration: 25 mg
  • Route of Administration: oral
Other Name: UCB34714




Primary Outcome Measures :
  1. Level of synaptic vesicle glycoprotein 2A (SV2A) receptor occupancy during the displacement scans [ Time Frame: Displacement scans (120 minutes) ]
    The receptor occupancy will be determined using occupancy plots from the apparent volume of distribution, Vapp values.

  2. Equilibrium tissue to plasma activity ratio (VT) of [11C]UCB-J [ Time Frame: Baseline (120 minutes) and Displacement scans (120 minutes) ]
    The equilibrium tissue to plasma activity ratio (VT) will be used to quantify [11C]UCB-J binding in each brain region of interest before and after administration of Brivaracetam and Levetiracetam.

  3. Tracer displacement halftimes [ Time Frame: Baseline (120 minutes) and Displacement scans (120 minutes) ]
    Tracer displacement halftimes will be estimated from Displacement scans and Baseline scans on the average standardized uptake value (SUV) for all regions over time during 60-minute timeframe.

  4. Tracer-exit corrected halftimes of Brivaracetam or Levetiracetam entry [ Time Frame: Baseline (120 minutes) and Displacement scans (120 minutes) ]
    Tracer-exit corrected halftimes of Brivaracetam or Levetiracetam entry will be estimated by subtracting the tracer clearance halftime from the displacement halftime.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion Criteria:

  • Subject is male or female and between 18 to 55 years of age (inclusive)
  • Subject is in good physical and mental health, in the opinion of the Investigator, determined on the basis of medical history, physical and neurological examinations, vital signs, 12-lead Electrocardiography (ECG), and clinical laboratory tests
  • Female subjects of childbearing potential must have a negative pregnancy test; female subjects of childbearing potential have to confirm that, for 1 month prior to the first administration of the study medication and during the entire study until the Safety Follow-Up (SFU) Visit she will either use a highly effective contraceptive method (eg, oral contraception, intrauterine device, diaphragm with spermicide) or abstain from sexual activity that can cause pregnancy

Exclusion Criteria:

Exclusion Criteria:

  • History or presence of clinically significant respiratory, gastrointestinal, renal, hepatic, pancreatic, hematological, cardiovascular, musculoskeletal, genitourinary, immunological, or dermatological disorders, or any type of cancer
  • Subject has a history of a neurological diagnosis, including but not limited to stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, or any other neurological disorder that may influence the outcome or analysis of the scan results
  • History of donation of more than 450 mL of blood within 60 days prior to dosing in the Yale PET center or planned donation before 30 days has elapsed since intake of study drug
  • The subject has Magnetic Resonance Imaging -incompatible (MRI - incompatible) implants and other contraindications for MRI, such as a pacemaker, artificial joints, non-removable body piercings, etc.
  • Subjects who have received a diagnostic or therapeutic radiopharmaceutical less than 7 days prior to participation in this study
  • Participation in other recent research studies < 1 month or < 1 year for studies involving ionizing radiation that would cause the subject to exceed the yearly dose limits for healthy volunteers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602860


Locations
Layout table for location information
United States, Connecticut
Ep0074 001
New Haven, Connecticut, United States
Sponsors and Collaborators
UCB Pharma
PRA Health Sciences
Yale University
Investigators
Layout table for investigator information
Study Director: UCB Cares +1-844-599-2273(UCB)

Layout table for additonal information
Responsible Party: UCB Pharma
ClinicalTrials.gov Identifier: NCT02602860     History of Changes
Other Study ID Numbers: EP0074
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: October 30, 2017
Last Verified: October 2017
Keywords provided by UCB Pharma:
SV2A
Levetiracetam
Brivaracetam
PET
Additional relevant MeSH terms:
Layout table for MeSH terms
Levetiracetam
Brivaracetam
Anticonvulsants
Nootropic Agents